Analyst Ratings February 6, 2026

Jefferies Cuts Genpact Price Target to $45, Keeps Buy Rating Amid Mixed Signals

Analyst trims valuation while company posts quarterly beats and guides to mid-single-digit growth framework

By Jordan Park G
Jefferies Cuts Genpact Price Target to $45, Keeps Buy Rating Amid Mixed Signals
G

Jefferies reduced its 12-month price target on Genpact Ltd. to $45 from $56 but kept a Buy rating. The move follows a quarter in which revenue met expectations and margins outperformed, and management reiterated a medium-term growth framework of at least 7% year-over-year growth for 2026. The stock, trading near its 52-week low, appears oversold based on RSI readings.

Key Points

  • Jefferies cut Genpact’s price target to $45 from $56 but retained a Buy rating.
  • Genpact reported Q4 2025 EPS of $0.97 and revenue of $1.32 billion, both modestly above consensus; stock fell slightly after hours.
  • Management’s 2026 revenue guidance aligns with a medium-term framework of at least 7% year-over-year growth; the company expects around 20 basis points of margin expansion despite investments in agentic solutions.

Jefferies has lowered its price objective for Genpact Ltd. (NYSE:G) to $45.00 from $56.00 while maintaining a Buy rating on the business process and services company. The brokerage's revision comes alongside the company’s most recent quarterly results and management commentary on near-term targets.

Genpact shares were trading at $37.70 at the time of the note, close to a 52-week low of $37.49. InvestingPro analysis cited in the brokerage note describes the stock as appearing undervalued, with the relative strength index indicating the security is in oversold territory.

Jefferies framed the price-target cut in the context of Genpact’s latest financials, which showed revenues roughly in line with its internal expectations while margins came in above the firm’s forecast. Management has outlined revenue guidance for 2026 that Jefferies said is consistent with the company’s stated medium-term growth framework of at least 7% year-over-year growth.

On profitability, Genpact anticipates driving about 20 basis points of margin expansion year-over-year, even as it continues to invest in so-called agentic solutions. Jefferies described those investments as ongoing and expects they will be balanced with margin improvement efforts.

Because of what it called a "quieter start to 1Q," Jefferies is modestly reducing its 2026 revenue projection for Genpact, but it left its adjusted earnings-per-share estimate unchanged at $4.03, which aligns with management’s guidance.

Those analyst adjustments occur against the backdrop of Genpact’s reported fourth-quarter 2025 results, which topped consensus estimates. The company posted earnings per share of $0.97 versus an expectation of $0.94, and revenue of $1.32 billion compared with forecasts of $1.31 billion. Despite that topline and EPS beat, the stock slipped slightly in after-hours trading following the release.

There were no contemporaneous reports of mergers or acquisitions tied to Genpact, and Jefferies’ note did not reference any fresh analyst upgrades or downgrades. Investors will continue to monitor execution against the 2026 targets and how investments in agentic capabilities intersect with margin expansion.


Context and next steps: Market participants will be watching upcoming quarter-to-quarter revenue trends and margin progress as management implements investments while pursuing at least 7% annual growth through 2026.

Risks

  • A quieter start to the first quarter has prompted Jefferies to modestly lower its 2026 revenue forecast - impacting revenue growth expectations in the technology and business services sectors.
  • Ongoing investments in agentic solutions could weigh on near-term profitability if expected margin expansion does not materialize - affecting investors focused on margins and earnings in the IT services and outsourcing sector.
  • The stock is trading near its 52-week low and technical indicators suggest it is oversold, which could signal heightened volatility for equity investors.

More from Analyst Ratings

Stifel Lowers JFrog Target Citing AI-Driven Security Concerns; Maintains Buy Rating Feb 22, 2026 HSBC Lowers Synopsys Rating to Hold, Flags 2026 as Transition Year Feb 21, 2026 DA Davidson Cuts Uber Price Target Citing Elevated Investment; Buy Rating Intact Feb 20, 2026 Freedom Capital Markets Raises Freeport-McMoRan to Buy, Cites Copper Supply Tightness Feb 20, 2026 BofA Lifts CF Industries Price Target After Strong Q4 EBITDA; Maintains Underperform Rating Feb 20, 2026